-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GLS-012 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GLS-012 in Solid Tumor Drug Details: GLS-012 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DSP-0187 in Narcolepsy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DSP-0187 in Narcolepsy Drug Details: DSP-0187 is under development for the treatment of narcolepsy and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RG-6006 in Ventilator Associated Pneumonia (VAP)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6006 in Ventilator Associated Pneumonia (VAP) Drug Details: RG-6006 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JNJ-6665 in Chronic Myelomonocytic Leukemia (CMML)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JNJ-6665 in Chronic Myelomonocytic Leukemia (CMML) Drug Details:JNJ-6665 is under development for the treatment of acute...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zabedosertib in Atopic Dermatitis (Atopic Eczema)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zabedosertib in Atopic Dermatitis (Atopic Eczema) Drug Details: Zabedosertib (BAY-1834845) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Moxidectin in Helminthiasis (Parasitic Worm Infestation)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Moxidectin in Helminthiasis (Parasitic Worm Infestation) Drug Details: Moxidectin is a semisynthetic derivative of nemadectin...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lipocurc in Colon Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Lipocurc in Colon CancerDrug Details:Liposomal curcumin is under development for the treatment of metastatic cancer, advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vebreltinib in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vebreltinib in Solid Tumor Drug Details: APL-101 (CBT-101) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vebreltinib in Renal Cell Carcinoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vebreltinib in Renal Cell Carcinoma Drug Details: APL-101 (CBT-101) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vebreltinib in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vebreltinib in Non-Small Cell Lung Cancer Drug Details: APL-101 (CBT-101) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vebreltinib in Central Nervous System (CNS) Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vebreltinib in Central Nervous System (CNS) Tumor Drug Details: APL-101 (CBT-101) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vebreltinib in Adenocarcinoma Of The Gastroesophageal Junction
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vebreltinib in Adenocarcinoma Of The Gastroesophageal Junction Drug Details: APL-101 (CBT-101) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tovorafenib in Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tovorafenib in Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) Drug Details: Tovorafenib (TAK-580 (MLN2480))...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Furosemide in Congestive Heart Failure (Heart Failure)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Furosemide in Congestive Heart Failure (Heart Failure) Drug Details:Furosemide (Furoscix) is a sulfamoylanthranilic acid derivative, acts...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bempedoic Acid in Cardiovascular Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bempedoic Acid in Cardiovascular Disease Drug Details: Bempedoic acid (Nexletol) is a non-statin lipid lowering...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pritumumab in Low-Grade Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pritumumab in Low-Grade Glioma Drug Details: Pritumumab is under development for the treatment of brain...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Geptanolimab in Malignant Mesothelioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Geptanolimab in Malignant Mesothelioma Drug Details:Geptanolimab (CBT-501) is under development for the treatment of cancers such...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Geptanolimab in Adenocarcinoma Of The Gastroesophageal Junction
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Geptanolimab in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:Geptanolimab (CBT-501) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Geptanolimab in Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Geptanolimab in Ovarian Cancer Drug Details:Geptanolimab (CBT-501) is under development for the treatment of cancers such...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Geptanolimab in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Geptanolimab in Colorectal Cancer Drug Details:Geptanolimab (CBT-501) is under development for the treatment of cancers such...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.